DFX Intelligence

Data Factory

Private equityFirmventure with pe activity · probableunsized

MPM Bioimpact

Private Equity

Boston, MA

MPM BioImpact is building companies to transform patient outcomes.

This is the graph view. The full profile, with its team, deals and sources, is on Private Equity.Open the full profile →

Search this name across graphsid dfx:pe:4f4be7da-1ee3-403d-b945-f4b1d769a063

Data as of Sep 17, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 20, 2026, 6:31 PM UTC and rebuilt at most every 15 minutes.

Relationships: 62
Dated events: 40
On other graphs: 2
Observed: Sep 13, 2026 to Sep 17, 2026
32 observations

Across DFX

same identity by shared identifier, citation, or a bridge measured by hand

Venture Capitalidentity

MPM Bioimpact

Venture manager · shared crd

RIA / Wealth Managementidentity

MPM BIOIMPACT

Registered adviser · shared crd

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Funds: 1
PE funds: 0
Vintages: 2022 to 2022
Regulatory AUM: $3.3B
Investments: 24
Active investments: 16
Size band: UNSIZEDderivedno Private Equity Fund GAV on a filing from 2021 or later
Stated sectors: life_sciences
Latest ADV filing: Jun 26, 2024
Employees (ADV): 50
Website: mpmbioimpact.com

Funds

Fund	Vintage	Lifecycle	ADV type	Form D sold	GAV	LPs
MPM Bioventures 2022, L.P.	2022	Early deployment	Venture Capital Fund	n/a	$345M	0

Investments

Company	State	Role	Control	Invested	Exited	Status
Protego Biopharma, Inc.	CA	minority	minority	Dec 1, 2025	n/a	active
Crossbow Therapeutics, Inc.	Ma	unknown	unknown	n/a	n/a	active
Cullinan Oncology	n/a	unknown	unknown	n/a	n/a	active
Firefly Bio, Inc.	CA	unknown	unknown	n/a	n/a	active
Aktis Oncology, Inc.	Ma	unknown	unknown	n/a	n/a	active
Antiva Biosciences	n/a	unknown	unknown	n/a	n/a	unknown
Arialys	n/a	unknown	unknown	n/a	n/a	unknown
Dyne Therapeutics	n/a	unknown	unknown	n/a	n/a	unknown
Entrada Therapeutics	n/a	unknown	unknown	n/a	n/a	unknown
K2	n/a	unknown	unknown	n/a	n/a	unknown
NextPoint Therapeutics, Inc.	Ma	unknown	unknown	n/a	n/a	unknown
Recode TX	n/a	unknown	unknown	n/a	n/a	unknown
Tizona Therapeutics, Inc.	n/a	unknown	unknown	n/a	n/a	unknown
Reunion Neuroscience, Inc.	Nj	unknown	unknown	n/a	n/a	active
Antivabio	n/a	unknown	unknown	n/a	n/a	active
Ashibio	n/a	unknown	unknown	n/a	n/a	active
Umoja Biopharma, Inc.	n/a	unknown	unknown	n/a	n/a	active
Photys Therapeutics, Inc.	n/a	unknown	unknown	n/a	n/a	active
AstronauTx	n/a	unknown	unknown	n/a	n/a	active
Protego	n/a	unknown	unknown	n/a	n/a	active
elevatebio	n/a	unknown	unknown	n/a	n/a	active
Fable	n/a	unknown	unknown	n/a	n/a	active
Aktis	n/a	unknown	unknown	n/a	n/a	active
Frontier Medicines	n/a	unknown	unknown	n/a	n/a	active

Relationships

Invested in (24)

→ AktisCompanyunknown
factDFX's own graph, The subject's own site
→ FableCompanyunknown
factDFX's own graph, The subject's own site
→ Photys Therapeutics, Inc.Companyunknown
factDFX's own graph, The subject's own site
→ Crossbow Therapeutics, Inc.Companyunknown
factDFX's own graph, The subject's own site
→ elevatebioCompanyunknown
factDFX's own graph, The subject's own site
→ AntivabioCompanyunknown
factDFX's own graph
→ Umoja Biopharma, Inc.Companyunknown
factDFX's own graph, The subject's own site
→ Aktis Oncology, Inc.Companyunknown
factDFX's own graph
→ ProtegoCompanyunknown
factDFX's own graph, The subject's own site
→ AstronauTxCompanyunknown
factDFX's own graph, The subject's own site
→ Cullinan OncologyCompanyunknown
factDFX's own graph, The subject's own site
→ AshibioCompanyunknown
factDFX's own graph, The subject's own site
→ Frontier MedicinesCompanyunknown
factDFX's own graph, The subject's own site
→ Firefly Bio, Inc.Companyunknown
factDFX's own graph
→ Reunion Neuroscience, Inc.Companyunknown
factDFX's own graph, The subject's own site
→ Protego Biopharma, Inc.Companyminority
Dec 1, 2025 to presentfactDFX's own graph
→ Antiva BiosciencesCompanyunknown
factThe subject's own site
→ ArialysCompanyunknown
factThe subject's own site
→ Dyne TherapeuticsCompanyunknown
factThe subject's own site
→ Entrada TherapeuticsCompanyunknown
factThe subject's own site
→ K2Companyunknown
factThe subject's own site
→ NextPoint Therapeutics, Inc.Companyunknown
factThe subject's own site
→ Recode TXCompanyunknown
factThe subject's own site
→ Tizona Therapeutics, Inc.Companyunknown
factThe subject's own site

Employs (21)

→ Ying Huang, Ph.D.PersonStrategic Advisor, APAC
factThe subject's own site
→ Luke Evnin, Ph.D.PersonAdvisor
factThe subject's own site
→ Ansbert S GadickePersonTrustee
Jan 1, 2012 to presentfactForm ADV
→ Robert Samuel RisoleoPersonGeneral Counsel
Jan 1, 2024 to presentfactForm ADV
→ Brendan Michael FureyPersonChief Compliance Officer
Nov 1, 2022 to presentfactForm ADV
→ Christiana Goh BardonPersonTrustee
Nov 1, 2015 to presentfactForm ADV
→ Paul KargerPersonTrustee
Jan 1, 2015 to presentfactForm ADV
→ Kristen Lee LaguerrePersonPartner, Finance And Operations
Oct 1, 2019 to presentfactForm ADV
→ Todd FoleyPersonManaging Director
Nov 1, 2015 to presentfactForm ADV
→ Luke Basil EvninPersonMember
Dec 1, 1999 to presentfactForm ADV
→ Steven St. PeterPersonManaging Director
Jan 1, 2004 to Mar 18, 2013inferenceForm ADV
→ Vaughn KailianPersonManaging Director
May 1, 2005 to Apr 1, 2015inferenceForm ADV
→ James Paul ScopaPersonManaging Director
Nov 1, 2015 to Mar 30, 2018inferenceForm ADV
→ John W. Vander VortPersonManaging Director, Chief Operating Officer & Chief Compliance Officer
May 1, 2005 to Sep 19, 2013inferenceForm ADV
→ Edward Martin HurwitzPersonManaging Director
Nov 1, 2015 to Mar 30, 2023inferenceForm ADV
→ Jeff William CrispenPersonChief Compliance Officer
Mar 1, 2022 to Nov 17, 2022inferenceForm ADV
→ Nicholas Myles McgrathPersonGeneral Counsel And Chief Compliance Officer
Jun 1, 2019 to Mar 23, 2022inferenceForm ADV
→ Howard Bruce RubinPersonChief Compliance Officer
Mar 1, 2018 to Jul 16, 2019inferenceForm ADV
→ Lauren CauleyPersonChief Financial Officer
Nov 1, 2015 to Jul 16, 2019inferenceForm ADV
→ Sarah ReedPersonChief Operating Officer And General Counsel
Nov 1, 2015 to Jul 16, 2019inferenceForm ADV
→ Bard GeesamanPersonManaging Director
Nov 1, 2015 to Mar 28, 2019inferenceForm ADV

Manages (1)

→ MPM Bioventures 2022, L.P.FundPrivate Equity Fund
Mar 30, 2023 to presentfactForm ADV

Owns (4)

← MPM Capital LLCFirmMember
Nov 1, 2015 to presentfactForm ADV
← MPM Founders LLCFirmMember
Dec 1, 1999 to presentfactForm ADV
← Gadicke 2012 Irrevocable TrustFirmMember
Nov 1, 2015 to presentfactForm ADV
← Ansbert K. Gadicke 2015 Irrevocable Trust IIFirmMember
Nov 1, 2015 to presentfactForm ADV

Dated events

1 bookkeeping events (roster, classification and holdings changes) folded below

Occurred
Aug 11, 2026
Firm news
K2 Therapeutics Appoints Dr. Ying Huang as Chief Executive Officer and Announces $50 Million Seed Financing
The subject's own siteobserved 3 days ago
Occurred
Jul 29, 2026
Firm news
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
The subject's own siteobserved 3 days ago
Occurred
Jun 8, 2026
Firm news
Johnson & Johnson to Acquire Firefly Bio, Inc.
The subject's own siteobserved 3 days ago
Occurred
Feb 9, 2026
Firm news
Lilly to acquire Orna Therapeutics to advance cell therapies
The subject's own siteobserved 3 days ago
Occurred
Mar 31, 2025
Firm news
Orna Therapeutics Appoints Joseph Bolen, Ph.D., an MPM BioImpact Entrepreneur Partner, as Chief Executive Officer
The subject's own siteobserved 3 days ago
Occurred
Jan 8, 2025
Firm news
MPM BioImpact Appoints Brian Shuster, Experienced in Healthcare Corporate Development, as Entrepreneur Partner
The subject's own siteobserved 3 days ago
Occurred
Jan 8, 2025
Firm news
MPM BioImpact Announces Promotion of Rami Rahal, Ph.D., to Partner
The subject's own siteobserved 3 days ago
Occurred
Nov 14, 2024
Firm news
Dr. Michael Ehlers Joins MPM BioImpact as Entrepreneur Partner – Endpoints News
The subject's own siteobserved 3 days ago
Occurred
Nov 14, 2024
Firm news
Michael Ehlers, M.D., Ph.D., Experienced R&D Leader and Accomplished Biotechnology Executive, Appointed as MPM BioImpact Entrepreneur Partner
The subject's own siteobserved 3 days ago
Occurred
Oct 1, 2024
Firm news
AstronauTx Appoints Jane Rhodes as Chief Executive Officer and Expands Executive Team
The subject's own siteobserved 3 days ago
Occurred
Jul 9, 2024
Firm news
Aktis Oncology Appoints Akos Czibere, MD, PhD, Chief Medical Officer
The subject's own siteobserved 3 days ago
Occurred
May 23, 2024
Firm news
Orna Therapeutics Announces Strategic Acquisition of ReNAgade Therapeutics to Solidify Leadership in Circular RNA Therapies
The subject's own siteobserved 3 days ago
Occurred
Apr 11, 2024
Firm news
MPM BioImpact Appoints Frank Neumann, M.D., Ph.D., Distinguished Expert in Clinical Development, as Entrepreneur Partner
The subject's own siteobserved 3 days ago
Occurred
Feb 27, 2024
Firm news
ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer
The subject's own siteobserved 3 days ago
Occurred
Jan 1, 2024
Person joined
Robert Samuel Risoleo joined Schedule A of MPM Bioimpact as General Counsel
Form ADVobserved 6 days ago
Occurred
Oct 10, 2023
Firm news
AstronauTx Closes $61M Series A to Create New Alzheimer’s Treatments
The subject's own siteobserved 3 days ago
Occurred
Sep 28, 2023
Firm news
Deka Biosciences Closes USD $20 Million Series B2 Financing
The subject's own siteobserved 3 days ago
Occurred
Apr 27, 2023
Firm news
Antiva Biosciences Closes $53 Million Series E Equity Financing
The subject's own siteobserved 3 days ago
Occurred
Mar 30, 2023
Person left
Edward Martin Hurwitz (Managing Director) no longer on Schedule A of MPM Bioimpact
Form ADVobserved 6 days ago
Occurred
Nov 17, 2022
Person left
Jeff William Crispen (Chief Compliance Officer) no longer on Schedule A of MPM Bioimpact
Form ADVobserved 6 days ago
Occurred
Nov 1, 2022
Person joined
Brendan Michael Furey joined Schedule A of MPM Bioimpact as Chief Compliance Officer
Form ADVobserved 6 days ago
Occurred
Jun 2, 2022
Firm news
The Health of Life Sciences Investment Climate — Chris Bardon (GBR Capital Interview)
The subject's own siteobserved 3 days ago
Occurred
Mar 23, 2022
Person left
Nicholas Myles Mcgrath (General Counsel And Chief Compliance Officer) no longer on Schedule A of MPM Bioimpact
Form ADVobserved 6 days ago
Occurred
Mar 1, 2022
Person joined
Jeff William Crispen joined Schedule A of MPM Bioimpact as Chief Compliance Officer
Form ADVobserved 6 days ago
Occurred
Jul 16, 2019
Person left
Howard Bruce Rubin (Chief Compliance Officer) no longer on Schedule A of MPM Bioimpact
Form ADVobserved 6 days ago
Occurred
Jul 16, 2019
Person left
Sarah Reed (Chief Operating Officer And General Counsel) no longer on Schedule A of MPM Bioimpact
Form ADVobserved 6 days ago
Occurred
Jul 16, 2019
Person left
Lauren Cauley (Chief Financial Officer) no longer on Schedule A of MPM Bioimpact
Form ADVobserved 6 days ago
Occurred
Jun 1, 2019
Person joined
Kristen Lee Laguerre joined Schedule A of MPM Bioimpact as Managing Director, Finance
Form ADVobserved 6 days ago
Occurred
Jun 1, 2019
Person joined
Nicholas Myles Mcgrath joined Schedule A of MPM Bioimpact as General Counsel And Chief Compliance Officer
Form ADVobserved 6 days ago
Occurred
Mar 28, 2019
Person left
Bard James Geesaman (Managing Director) no longer on Schedule A of MPM Bioimpact
Form ADVobserved 6 days ago
Occurred
Mar 30, 2018
Person left
James Paul Scopa (Managing Director) no longer on Schedule A of MPM Bioimpact
Form ADVobserved 6 days ago
Occurred
Mar 1, 2018
Person joined
Howard Bruce Rubin joined Schedule A of MPM Bioimpact as Chief Compliance Officer
Form ADVobserved 6 days ago
Occurred
Nov 1, 2015
Person joined
Edward Martin Hurwitz joined Schedule A of MPM Bioimpact as Managing Director
Form ADVobserved 6 days ago
Occurred
Nov 1, 2015
Person joined
Bard Geesaman joined Schedule A of MPM Bioimpact as Chief Compliance Officer
Form ADVobserved 6 days ago
Occurred
Nov 1, 2015
Person joined
Christiana Goh Bardon joined Schedule A of MPM Bioimpact as Trustee
Form ADVobserved 6 days ago
Occurred
Nov 1, 2015
Person joined
Lauren Cauley joined Schedule A of MPM Bioimpact as Chief Financial Officer
Form ADVobserved 6 days ago
Occurred
Nov 1, 2015
Person joined
Sarah Reed joined Schedule A of MPM Bioimpact as Chief Operating Officer And General Counsel
Form ADVobserved 6 days ago
Occurred
Apr 1, 2015
Person left
Vaughn Kailian (Managing Director) no longer on Schedule A of MPM Bioimpact
Form ADVobserved 6 days ago
Occurred
Jan 1, 2015
Person joined
Paul Karger joined Schedule A of MPM Bioimpact as Trustee
Form ADVobserved 6 days ago

Show 1 bookkeeping events

Occurred
Mar 30, 2023
MPM Bioventures 2022, L.P. first reported on Form ADV by MPM Bioimpact (Private Equity Fund), GAV $337,703,600

Who to call

the organisation, the role and the published line, with the filing or website that published it; revealed to signed-in accounts

The firm's published line

Revealable: 1 business phone (Form ADV), 1 office address (Form ADV), 1 website (Form ADV) · as of 2026-09-13

Also named here, with no published line of their own (reach them through the firm): Ying Huang, Ph.D. (Strategic Advisor, APAC), Luke Evnin, Ph.D. (Advisor), Ansbert S Gadicke (Trustee), Robert Samuel Risoleo (General Counsel), Brendan Michael Furey (Chief Compliance Officer), Christiana Goh Bardon (Trustee), Paul Karger (Trustee), Kristen Lee Laguerre (Partner, Finance And Operations), Todd Foley (Managing Director), Luke Basil Evnin (Member).

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Provenance

Graph: Private Equity
Canonical id: dfx:pe:4f4be7da-1ee3-403d-b945-f4b1d769a063
First observed: Sep 13, 2026
Last observed: Sep 17, 2026 3 days ago
Source families: Federal regulator filings, Firm and issuer disclosures
3 registered feeds stand behind this record; each fact above carries its own dates and, where the publisher serves one, its document.
Resolution: Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.

MPM Bioimpact

Private Equity

Boston, MA

MPM BioImpact is building companies to transform patient outcomes.

This is the graph view. The full profile, with its team, deals and sources, is on Private Equity.Open the full profile →

Search this name across graphsid dfx:pe:4f4be7da-1ee3-403d-b945-f4b1d769a063

Data as of Sep 17, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 20, 2026, 6:31 PM UTC and rebuilt at most every 15 minutes.